Shorted
Alterity Therapeutics logo
ATH

Alterity Therapeutics

Pharmaceuticals, Biotechnology & Life Sciences

Alterity Therapeutics Limited focuses on developing therapies to treat neurodegenerative diseases associated with aging, like Alzheimer's and Parkinson's disease. The company leverages a novel drug development platform aimed at targeting misfolded proteins. Positioned as a pioneer in this field, Alterity aims to address significant unmet needs in the neurosciences market.

Short position

short percentage0.02%
reported shorts45K
shares on issue229.151M

Alterity Therapeutics (ASX:ATH) has 0.02% of its shares on issue reported as short positions as of 5 Oct 2026, or about 45,003 shares. Over the past 30 days that figure has fallen 0.09 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 1.18% in January 2024. ATH is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Alterity Therapeutics (ATH) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
28 Sept

Will Alterity (ASX:ATH) Fund Its Pivotal MSA Trial?

Highlights Alterity has laid out a sharper regulatory path for its lead drug in multiple system atrophy. US regulators have agreed a single pivotal study plus supporting data could back a marketing application. Funding the pivotal programme through partnering or capital raising is now the central question. Alterity Therapeutics (ASX:ATH) has set out a clearer late-stage path for its lead drug candidate in multiple system atrophy, telling a US healthcare conference this month that regulators h...

Continue reading
Kalkine
Neutral
18 Sept

What Does Alterity Therapeutics (ASX:ATH) Latest Conference Presentation Update Mean?

Highlights Alterity Therapeutics Limited (ASX:ATH) has confirmed a conference presentation update. The update keeps the stock in focus within Healthcare Stocks. Conference presentations are a common way for companies to communicate an overview of their operations to a broader audience of market participants. Alterity Therapeutics is a clinical-stage biotechnology company developing therapies targeting neurodegenerative diseases. The company has confirmed a conference presentation update, a de...

Continue reading
Kalkine
Neutral
1 Sept

Could Alterity (ASX:ATH) Draw More Attention Across Smallcap Stocks?

Highlights The clinical stage biotech executed an underwriting agreement covering the exercise of listed options that reached expiry at the end of August. The arrangement gives the company balance sheet certainty at a moment when small cap capital markets remain selective and cautious. Funds are directed toward continued development of the lead therapeutic candidate targeting a rare neurodegenerative disorder. Alterity Therapeutics (ASX:ATH), the Melbourne-based clinical stage biotechnology c...

Continue reading
Kalkine
Neutral
31 Aug

Alterity Therapeutics Secures Underwriting Deal to Raise Up to A$7.96 Million Through ATHO Listed Options

Alterity Therapeutics (ASX:ATH) has formalized an underwriting agreement with MST Financial Services Pty Ltd to back the exercise of up to 8,400,000 unexercised ATHO listed options before their expiry on 31 August 2026. The transaction is projected to generate proceeds ranging from approximately A$4.2 million to A$7.96 million before costs. Key Points MST Financial Services Pty Ltd appointed as sole underwriter for up to 8,400,000 ATHO listed options, each exercisable at A$0.50 per option Dep...

Continue reading
Kalkine
Neutral
12 Aug

Why Is Alterity Therapeutics (ASX:ATH) Back in Focus Among ASX Healthcare Stocks?

Highlights Alterity Therapeutics is in focus after a fresh company disclosure added new context to the public record. The healthcare stocks lens centres on clinical progress, regulatory pathways, commercial execution and funding discipline. The broader Australian market backdrop remains important when reading company-specific developments. Australian shares are being assessed against a shifting mix of company updates, sector conditions and global market signals, making fresh disclosures espec...

Continue reading